IGC Pharma Inc Stock Price, News & Analysis

India Globalization Capital, Inc. (IGC) announced a new patent (#11,351,152) for a method to treat seizure disorders. This patent, issued by the USPTO, covers the use of cannabidiol (CBD) combined with other compounds to potentially reduce side effects from traditional anticonvulsants. The company aims to explore treatment pathways for both humans and pets, particularly dogs and cats, as approximately 50 million people globally suffer from epilepsy, with 3.8 million dogs at risk of seizures. IGC is also involved in cannabinoid therapy research for Alzheimer's.

India Globalization Capital has appointed Claudia Grimaldi as a non-independent Director effective March 23, 2022. With nearly 12 years at IGC, she brings extensive experience in SEC and NYSE compliance and is currently the Vice President and Chief Compliance Officer. Ms. Grimaldi aims to offer diverse perspectives and advance the company’s commitment to achieving ESG goals, particularly for the IGC-AD1 project targeting Alzheimer’s disease. IGC continues to focus on cannabinoid-based therapies and has recently completed a Phase 1 clinical trial.

India Globalization Capital reported Q3 results for the fiscal year 2022. The Company appointed James Moran to its Board of Directors, enhancing its expertise in healthcare. It completed a Phase 1 clinical trial for IGC-AD1, aimed at treating Alzheimer’s disease, showing promising results in reducing Neuropsychiatric Symptoms. The Life Sciences segment generated $134 thousand in revenue, while the Infrastructure segment brought in $8 thousand. The net loss was approximately $2.38 million, or ($0.05) per share. R&D expenses rose to $377 thousand, reflecting increased clinical trial activities.

India Globalization Capital, Inc. (IGC) has appointed former Congressman Jim Moran as an independent Director on its Board. With 24 years in Congress, Moran is known for his bipartisan leadership and focus on healthcare, environment, and defense. He will provide valuable insights as IGC advances its Phase 2/3 trials of the THC-based investigational drug for Alzheimer’s disease. Moran's experience in innovative research could strengthen IGC’s initiatives in cannabinoid-based therapies, aiming for FDA-approved clinical trials.

India Globalization Capital (IGC) announced positive results from its Phase 1 clinical trial for IGC-AD1, a cannabinoid-based drug for Alzheimer's disease. The primary endpoint focused on safety and tolerability was successfully met, with minimal adverse events reported. The trial involved 36 elderly patients who showed no serious safety concerns. The company plans to advance the trial to assess efficacy, pending FDA approval. IGC aims to improve the quality of life for Alzheimer's patients through further testing of IGC-AD1.

India Globalization Capital, Inc. (IGC) has announced preliminary results from its Phase 1 clinical trial for IGC-AD1, a cannabis-based drug candidate for Alzheimer’s disease. Key insights into pharmacokinetics and genotyping have been obtained, crucial for determining optimal dosing in future trials pending FDA approval. The trial showed mean T_max values of 2.15 hours for THC and 1.9 hours for OH-THC, and mean T_1/2 values of 3.60 hours for THC and 3.30 hours for OH-THC, suggesting safe dosing frequencies. Further trials are planned to establish the drug's safety and efficacy.

India Globalization Capital, Inc. (IGC) announced preliminary positive findings from its Phase 1 clinical trial for IGC-AD1, a THC-based drug aimed at treating Alzheimer’s symptoms. The trial highlighted significant decreases in anxiety (50-60%) and agitation (35-60%) among participants. The results were shared in a Clinical/Statistical Report filed with the FDA. IGC plans to expand the study with a placebo-controlled trial pending FDA approval. Alzheimer's affects 50 million globally, with no approved medications for symptom relief, underscoring the potential impact of IGC-AD1.

India Globalization Capital, Inc. (NYSE American: IGC) reported financial results for Q2 of fiscal 2022, ending September 30, 2021. Revenue declined to approximately $56,000 from $125,000 in the same quarter last year, with Infrastructure segment revenue at $3,000 down from $67,000. SG&A expenses surged to about $4.1 million due to inventory theft and legal costs. R&D expenses increased slightly to $276,000 and the net loss widened to approximately $4.3 million or ($0.08) per share. The company is progressing with the Phase 1 trial of its THC-based drug IGC-AD1 for Alzheimer’s, expecting future FDA submissions.

India Globalization Capital, Inc. (IGC) held its Annual Meeting of Shareholders on October 15, 2021, where all voting matters in the Definitive Proxy filed with the SEC were approved.

Key approvals included:

• Election of Richard Prins to the board until 2024.
• Ratification of Manohar Chowdhry & Associates as the independent accounting firm for fiscal year 2022.
• Granting 3,500,000 shares to employees and consultants based on performance metrics.
• Proposal to adjourn the meeting if necessary to solicit more proxy votes.